Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Tumours comprise a heterogeneous collection of cells with distinct genetic and phenotypic
properties that can differentially promote progression, metastasis and drug resistance …

With advances in sequencing and instrument technology, bioinformatics analysis is being
applied to batches of massive cells at single-cell resolution. High-throughput single-cell …

Subclonal reconstruction from bulk tumor DNA sequencing has become a pillar of cancer
evolution studies, providing insight into the clonality and relative ordering of mutations and …

Cellular heterogeneity within and across tumors has been a major obstacle in
understanding and treating cancer, and the complex heterogeneity is masked if bulk tumor …

Recurrent successions of genomic changes, both within and between patients, reflect
repeated evolutionary processes that are valuable for the anticipation of cancer progression …

Circulating tumor cells are tumor cells with high vitality and high metastatic potential that
invade and shed into the peripheral blood from primary solid tumors or metastatic foci. Due …

Drug resistance mediated by clonal evolution is arguably the biggest problem in cancer
therapy today. However, evolving resistance to one drug may come at a cost of decreased …

Understanding the clonal architecture and evolutionary history of a tumour poses one of the
key challenges to overcome treatment failure due to resistant cell populations. Previously …

Cancer arises through the accumulation of somatic mutations over time. An understanding of
the sequence of events during this process should allow both earlier diagnosis and better …